2019
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
Adamia S, Abiatari I, Amin S, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi N, Anderson K. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia 2019, 34: 167-179. PMID: 31182781, PMCID: PMC6901818, DOI: 10.1038/s41375-019-0498-5.Peer-Reviewed Original ResearchConceptsMultiple myelomaPlasma cellsOvert multiple myelomaPatient outcomesMM cellsMM pathogenesisLet-7fMicroRNA deregulationRegulation of microRNAsCD138Certain miRsMyelomaMiRDependent gene expressionDeregulated expressionMiR-mediated regulationSignificant numberEpigenetic lesionsTarget genesMM genomesExpressionGene expressionEarly stagesCellsPatients
2013
Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma
Wang X, Yan Z, Fulciniti M, Li Y, Gkotzamanidou M, Amin S, Shah P, Zhang Y, Munshi N, Li C. Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia 2013, 28: 894-903. PMID: 23925045, PMCID: PMC4155324, DOI: 10.1038/leu.2013.233.Peer-Reviewed Original ResearchConceptsCell cycle arrestCycle arrestCoexpression analysisCell cycle arrest genesHyperdiploid MMCell cycle arrest pathwaysNon-hyperdiploid multiple myelomaDistinct chromosomal alterationsMyeloma subtypeMultiple myelomaTranscription factorsArrest pathwaysSp1Low coexpressionProper regulationHuman cancersDifferent survival outcomesChromosomal alterationsPlasma B cellsCoexpressionCell linesNovel hypothesisSurvival outcomesMyeloma proliferationClinical utility
2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
Tian Z, Zhao J, Tai Y, Amin S, Hu Y, Berger A, Richardson P, Chauhan D, Anderson K. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 2012, 120: 3958-3967. PMID: 22983447, PMCID: PMC3496955, DOI: 10.1182/blood-2012-01-401794.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBoron CompoundsCell DeathCell Line, TumorCell MovementCell SurvivalCluster AnalysisDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGlycineHumansImidazolesMiceMicroRNAsMultiple MyelomaProto-Oncogene Proteins c-pim-1PyridazinesSignal TransductionXenograft Model Antitumor AssaysConceptsMultiple myelomaMM cellsPim-1Tumor suppressor geneTranscriptional regulationPim-1 overexpressionBiochemical inhibitorsApoptotic signalingRole of miRTumor suppressorMiR33bMM cell viabilityCell deathPatient MM cellsMM xenograft modelNovel therapeutic strategiesLuciferase activityColony formationOverexpressionMiR profilingTumor pathogenesisInvestigational agentsCritical roleRegulationCell viability
2010
Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma
Mahindra A, Amin S, Sohani A, Motyckova G, Patel K, Vallet S, Pozzi S, Santo L, Cirstea D, Toomey C, Michaelson J, Hochberg E, Dal Cin P, Rodig S, Hideshima T, Anderson K, Munshi N, Raje N. Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. Blood 2010, 116: 4042. DOI: 10.1182/blood.v116.21.4042.4042.Peer-Reviewed Original ResearchMultiple myelomaMedullary plasmacytomaTissue microarrayMean overall survivalRisk of progressionPlasma cell disordersNew therapeutic approachesOverall survivalMale preponderanceMedian ageSolitary lesionMultiple lesionsPathological diagnosisPtch-1Plasma cellsTherapeutic approachesCell myelomaCell disordersPatientsSolid tumorsClonal proliferationMetastatic potentialPlasmacytomaMyelomaMolecular profilingElevated IL-17 produced by T h 17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Prabhala R, Pelluru D, Fulciniti M, Prabhala H, Nanjappa P, Song W, Pai C, Amin S, Tai Y, Richardson P, Ghobrial I, Treon S, Daley J, Anderson K, Kutok J, Munshi N. Elevated IL-17 produced by T h 17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115: 5385-5392. PMID: 20395418, PMCID: PMC2902136, DOI: 10.1182/blood-2009-10-246660.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsHealthy donor peripheral blood mononuclear cellsDonor peripheral blood mononuclear cellsIL-17Multiple myelomaBM mononuclear cellsMyeloma cell growthBone marrowBone marrow stromal cellsIL-22Mononuclear cellsHealthy donorsImmune functionT helper 17 (Th17) cellsElevated IL-17Observed immune dysfunctionSerum IL-17IL-23 productionBlood mononuclear cellsAnti-MM activityIL-17 receptorHuman multiple myelomaMurine xenograft modelImportant therapeutic targetMM pathobiology